United Therapeutics CorporationUTHRNASDAQ
LOADING
|||
Cash Generation Expanding
Trending higher, above historical average, strong compound growth.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$1.08B
↑ 104% above average
Average (9y)
$529.07M
Historical baseline
Range
High:$1.08B
Low:$-290.30M
CAGR
+14.0%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $1.08B | +44.5% |
| 2023 | $747.60M | +12.6% |
| 2022 | $663.70M | +39.0% |
| 2021 | $477.40M | -31.4% |
| 2020 | $696.40M | +339.9% |
| 2019 | $-290.30M | -148.9% |
| 2018 | $594.00M | +53.1% |
| 2017 | $387.90M | -35.4% |
| 2016 | $600.40M | +80.3% |
| 2015 | $333.01M | - |